Results 151 to 160 of about 263,101 (241)

Application Value of Blood Routine-Derived Indices for the Evaluation of Disease Activity in Systemic Lupus Erythematosus. [PDF]

Clin Med Insights Arthritis Musculoskelet Disord
Li M, Li Y, Pang L, Chen J, Shang S, Huang C.   +5 more
europepmc   +1 more source

Denosumab Offers Relatively Lower Initial Protection Against Osteoporotic Vertebral Fractures in Treatment‐Naive Patients Compared With Zoledronate

Clinical Pharmacology &Therapeutics, EarlyView.
We compared the initial efficacy of denosumab (Dmab) and zoledronate (ZOL) in treatment‐naive patients with osteoporosis. This cohort study, based on TriNetX data, evaluated the risks of fractures and mortality using Kaplan–Meier survival analyses, with hazard ratios (HRs) and 95% confidence intervals (CIs).
Ko‐Hsiu Lu, Shiow‐Ing Wang, Shun‐Fa Yang   +2 more
wiley   +1 more source

The ERβ Agonist, OSU-ERβ-012, Mitigates Inflammation in a Chimeric Model of Systemic Lupus Erythematosus. [PDF]

ACR Open Rheumatol
Zeno B, Bruckner S, Yuan H, Stahl M, Alexandrov T, Jablonski K, Lin J, Young NA, Jarjour WN.   +8 more
europepmc   +1 more source

Cardiorenal Outcomes of Dapagliflozin vs. Empagliflozin in Advanced Chronic Kidney Disease and Diabetes

Clinical Pharmacology &Therapeutics, EarlyView.
Target trial emulation of a multi‐institutional electronic health record network showed comparable cardiorenal effectiveness and safety of dapagliflozin versus empagliflozin in adults with type 2 diabetes and advanced‐stage chronic kidney disease.
Shih‐Hsuan Lin, Jia‐Jin Chen, Ching‐Chung Hsiao, Yu‐Wei Fang, Meng‐Ting Chen, Ming‐Hsien Tsai, Huang‐Yu Yang   +6 more
wiley   +1 more source

Two Cases of Systemic Lupus Erythematosus With Castleman Disease. [PDF]

Cureus
Bravo-Andrade AM, Ibarra-Burgos JA, Bacca-Gonzalez JM, Torres-Trujillo JA.   +3 more
europepmc   +1 more source

Financial Toxicity Associated with Biological Medicines: A Scoping Review

Clinical Pharmacology &Therapeutics, EarlyView.
Financial toxicity, defined as the economic burden experienced by patients due to medication and other healthcare costs and their consequences, such as material, psychosocial and behavioral effects, represents a significant concern for individuals receiving biological medicines.
Laura Sara Maria Saarukka, Kamilla Yamileva, Kari Linden, Anniina Simonen, Anna‐Riia Holmström   +4 more
wiley   +1 more source

Pneumococcal Sepsis Revealing Pediatric Systemic Lupus Erythematosus with Sjögren's Syndrome Overlap: A Case Report. [PDF]

Pediatr Rep
Accomando F, Albertazzi V, Girelli F, Biscarini M, Aricò MO, Valletta E.   +5 more
europepmc   +1 more source

Anifrolumab Dose Regimen Selection for a Phase 3 Trial in Lupus Nephritis

Clinical Pharmacology &Therapeutics, EarlyView.
In patients with systemic lupus erythematosus (SLE), increased type I interferon signaling is associated with increased disease activity across organs, including in the kidney, which can cause lupus nephritis (LN). Anifrolumab, which abrogates type I interferon signaling, is an approved treatment for moderate to severe SLE.
Joachim Almquist, Yen Lin Chia, Raj Tummala, Lynn Bertagnolli, David Jayne, Weifeng Tang, Catharina Lindholm   +6 more
wiley   +1 more source

Elevated interleukin-6 levels predict short-term flare in systemic lupus erythematosus. [PDF]

Front Immunol
Gracia Tello BDC, García-Bruñén JM, Corredor L, Allue Fantova N, Calvo Beguería EM, García-Muñío R, Pérez Abad L, Aramburu Llorente J, Martinez Muriel B, Vidales Miguélez P, Morante Mendoza RA, Martínez Artigot J, Chicano Nieto N, Álvarez Troncoso J, Martinez-Lostao L, Marín Ballvé A.   +15 more
europepmc   +1 more source

Causal correlations between inflammatory proteins and heart failure: A two‐sample Mendelian randomization analysis

ESC Heart Failure, Volume 12, Issue 2, Page 1374-1385, April 2025.
Abstract Aims Inflammation plays a critical role in both the development and progression of heart failure (HF), which is a leading cause of morbidity and mortality worldwide. However, the causality between specific inflammation‐related proteins and HF risk remains unclear.
Xian‐Guan Zhu, Gui‐Qin Liu, Ya‐Ping Peng, Li‐Ling Zhang, Xian‐Jin Wang, Liang‐Chuan Chen, Yuan‐Xi Zheng, Xue‐Jun Xiang, Rui Qiao, Xian‐He Lin   +9 more
wiley   +1 more source